Juan Garona1, Marina Pifano1, Alejandra M Scursoni2, Daniel E Gomez1, Daniel F Alonso3, Giselle V Ripoll1. 1. Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina. 2. Pathology Service, Iriarte Hospital of Quilmes, Buenos Aires, Argentina. 3. Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina dfalonso@unq.edu.ar.
Abstract
BACKGROUND/AIM: Desmopressin (dDAVP) is a synthetic peptide analog of vasopressin with antidiuretic and hemostatic properties. Recent experimental evidence have suggested that dDAVP can inhibit metastasis formation by agonist action on V2 vasopressin receptors present in both tumor and endothelial cells. We have examined the kinetics of dDAVP effect during metastatic colonization and its potential association with hemostasis. MATERIALS AND METHODS: The experimental metastasis assay was performed by injecting F3II mammary carcinoma cells into the lateral tail vein of syngeneic female BALB/c mice. RESULTS: Clinically relevant doses of dDAVP (0.3 to 2 μg/kg intravenously (i.v.)) produced a dose-dependent inhibition in the formation of lung nodules when administered during the first 24 hours after F3II tumor cell injection. The hemostatic agent tranexamic acid (10 mg/kg, i.v.) had no effect on metastasis formation in the same experimental conditions, while the anticoagulant enoxaparin (1 mg/kg, subcutaneously (s.c.)) did not modify the antimetastatic action of dDAVP. In vitro, dDAVP had a strong inhibitory effect on F3II cell colony formation. CONCLUSION: dDAVP interferes with early metastatic disease, and direct association of this effect with hemostatic mechanisms is unlikely. Copyright
BACKGROUND/AIM: Desmopressin (dDAVP) is a synthetic peptide analog of vasopressin with antidiuretic and hemostatic properties. Recent experimental evidence have suggested that dDAVP can inhibit metastasis formation by agonist action on V2 vasopressin receptors present in both tumor and endothelial cells. We have examined the kinetics of dDAVP effect during metastatic colonization and its potential association with hemostasis. MATERIALS AND METHODS: The experimental metastasis assay was performed by injecting F3II mammary carcinoma cells into the lateral tail vein of syngeneic female BALB/c mice. RESULTS: Clinically relevant doses of dDAVP (0.3 to 2 μg/kg intravenously (i.v.)) produced a dose-dependent inhibition in the formation of lung nodules when administered during the first 24 hours after F3II tumor cell injection. The hemostatic agent tranexamic acid (10 mg/kg, i.v.) had no effect on metastasis formation in the same experimental conditions, while the anticoagulant enoxaparin (1 mg/kg, subcutaneously (s.c.)) did not modify the antimetastatic action of dDAVP. In vitro, dDAVP had a strong inhibitory effect on F3II cell colony formation. CONCLUSION: dDAVP interferes with early metastatic disease, and direct association of this effect with hemostatic mechanisms is unlikely. Copyright
Authors: Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso Journal: Clin Exp Metastasis Date: 2016-05-05 Impact factor: 5.150
Authors: Juan Garona; Marina Pifano; Ulises D Orlando; Maria B Pastrian; Nancy B Iannucci; Hugo H Ortega; Ernesto J Podesta; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso Journal: Int J Oncol Date: 2015-04-03 Impact factor: 5.650
Authors: Marina Pifano; Juan Garona; Carla S Capobianco; Nazareno Gonzalez; Daniel F Alonso; Giselle V Ripoll Journal: Front Oncol Date: 2017-01-30 Impact factor: 6.244